In adult HIV patients on ART who have noninfectious diarrhea

Enough is Enough
NORMALIZE with MYTESI

  •  

    Important Safety Information about MYTESI

    MYTESI™ is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI.

    If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    Click to Read Full Prescribing Information

References:

  1. Food and Drug Administration. Approved Drug Products With Therapeutic Equivalence Evaluations (Orange Book).
    https://sservices.trialcard.com/Coupon/mytesi. Accessed March 2, 2017.
  2. Data on file. Napo Pharmaceuticals, Inc.
  3. MacArthur RD, Harkins TN, Brown SJ, et al. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT Trial): a randomized, double-blind, placebo-controlled, two-stage study. HIV Clin Trials. 2013;14(6):261–273.

HIV+ Patients Talk About Diarrhea

“It’s interrupting my daily routine…I’m becoming afraid of it.  It seems like I’m changing my life because of my diarrhea.”

    Male, age 62, HIV+ for 3 years

For noninfectious diarrhea in adults living with HIV who are on antiretroviral therapy

Know when your patients

have had ENOUGH…

Sometimes it’s about asking the right question…

Mytesi—the only treatment proven and FDA-approved for relief of diarrhea in people with HIV1

Results over time with Mytesi2†

Week 4 on Mytesi 125 mg BID

61% of patients had at least a 50% decrease in watery stools

 

Week 20 on Mytesi 125 mg BID

83% of patients had at least a 50% decrease in watery stools

Over half of patients had no watery stools at all (100% decrease)

†Daily diary data were evaluated in a supplemental analysis from all patients treated with Mytesi 125 mg BID in the ADVENT trial for up to 24 weeks. The average reduction in watery stools from baseline was determined by week.

In adult HIV patients on ART who have noninfectious diarrhea

When ENOUGH is ENOUGH,
NORMALIZE with MYTESI

Mytesi (crofelemer) is the only antidiarrheal that:

  • Works by normalizing water flow in the GI tract to provide symptomatic relief of diarrhea
  • Is not an opioid and does not affect GI motility3

 

Mytesi has been proven to have:

  • Minimal absorption, with plasma concentrations below the level of detection
  • No clinically relevant drug-drug interactions
  • No effect on viral load or CD4 counts
  • Adverse events comparable to those with placebo

For product information, adverse event reports, and product complaint reports, please contact:

Napo Pharmaceuticals, Inc.

San Francisco, CA 94105

email: napopharma@missionpharmacal.com

phone: (844) 722-8256

Enough is Enough
NORMALIZE with MYTESI

 
  •  

    Important Safety Information about MYTESI

    MYTESI™ is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI.

    If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    Click to Read Full Prescribing Information